U.S. IT Stock News

Xcel Energy (XEL) is back on investors’ radar after outlining a US$29b grid investment plan, securing a Colorado rate case settlement, and reaffirming earnings guidance, all while advancing several clean energy transition projects. See our latest analysis for Xcel Energy. After a choppier few months, with the 90 day share price return down 4.22%, Xcel Energy’s year to date share price return of 5.84% and 1 year total shareholder return of 19.02% suggest that momentum has been supported by its...

Shareholder votes and product launches put Mondelez in focus Mondelez International (MDLZ) has moved into the spotlight after shareholders rejected two governance related proposals at the May 20 annual meeting, while the company rolled out new limited edition OREO collaborations and marketing events. For investors, these developments raise questions on two fronts: how the current board structure and approach to environmental reporting may shape future decision making, and whether brand...

Distribution increase and production update set the tone for Sabine Royalty Trust (SBR) Sabine Royalty Trust (SBR) has declared a June 2026 cash distribution of $0.502990 per unit, supported by stronger oil and gas pricing even as monthly production volumes moved lower. See our latest analysis for Sabine Royalty Trust. Recent trading reflects that backdrop: despite a 1-day share price return that declined 1.02% to $77.76, the stock has a 7-day share price return of 4.00% and a 1-year total...

Dollar General (DG) is back in focus after reporting first quarter earnings that topped analyst expectations, lifting net sales, net income and same store sales, and prompting management to raise full year profit guidance. See our latest analysis for Dollar General. Even with the earnings beat and higher full year guidance, Dollar General’s recent share price performance has been weak. The stock is down 10.89% on a 1 month share price return basis and 24.21% year to date, while the 1 year...

In recent days, OneMain Holdings completed its first consumer loan securitization of 2026 while facing renewed scrutiny over slower growth and declining earnings versus peers, alongside ongoing legal and competitive pressures in nonprime lending. At the same time, commentators have highlighted a perceived valuation gap and weak financial strength scores, raising questions about how OneMain balances funding needs, risk management, and shareholder returns under these conditions. We’ll now...

Wondering whether Arthur J. Gallagher at around US$216 per share still stacks up as good value, or if the recent price action has changed the picture. The stock has risen 7.5% over the past week and 9.8% over the past month, yet is still down 15.6% year to date and has fallen 33.5% over the past year. This may prompt questions about whether expectations or perceived risk have shifted. Recent coverage around Arthur J. Gallagher has focused on its position within the insurance sector and how...

In May 2026, Trinity Capital completed a US$297.54 million fixed-income offering and announced a US$300.00 million follow-on equity raise, alongside first-quarter revenue of US$90.13 million versus US$65.39 million a year earlier and a slight dip in earnings per share. Insider share purchases during this period highlight management’s confidence in the business, even as the company continues to rely on external capital to fund its growth. We’ll now examine how Trinity’s recent fixed-income...

Bancorp (TBBK) is back in focus after recent commentary on potential Federal Reserve rate hikes raised questions about funding costs, net interest margins, and exposure to commercial real estate across regional bank portfolios. See our latest analysis for Bancorp. At a share price of US$54.11, Bancorp has seen its 1 month share price return fall 10.55% and its year to date share price return decline 20.03%. This is occurring even though the 1 year total shareholder return is 3.66% and the 5...

Why Kodiak Sciences Stock Is Back in Focus After GLOW2 Results Kodiak Sciences (KOD) is drawing fresh attention after reporting positive top line Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy, which has prompted accelerated regulatory plans and renewed interest in its ophthalmology pipeline. See our latest analysis for Kodiak Sciences. The GLOW2 data initially helped extend Kodiak Sciences’ strong multi year run, with the 1 year total shareholder return now very large relative to the...

In recent days, Microchip Technology announced U.S. export-license approval for advanced FPGA development in Armenia, alongside new AI-focused PCIe 6.0 and CXL 3.1 retimers and 3.3 kV SiC power modules aimed at data-center and high-voltage applications. These developments expand Microchip’s role in AI infrastructure and global engineering while adding cost-focused dsPIC33CK controllers and a new independent board member. Together, the export-license clearance and AI/data-center product...

In early June 2026, a wrongful death lawsuit was filed against Atmos Energy and several other parties after a gas explosion destroyed a Dallas apartment complex, killing three residents including 81-year-old community activist Sylvia Collins. The case puts Atmos Energy’s safety practices, infrastructure maintenance, and coordination with contractors under legal and public scrutiny, potentially influencing how regulators and communities view the company’s role in local energy systems. Now...

ADMA Biologics (ADMA) is back in the spotlight after being placed on the Zacks Rank #5 Strong Sell list, alongside fresh legal investigations, a critical short seller report, and the withdrawal of long term guidance. See our latest analysis for ADMA Biologics. The recent legal probes, short seller allegations and earnings downgrades have coincided with a sharp reset in sentiment, with ADMA’s share price falling 20.9% over the past month and 55.4% year to date, despite a very large 5 year...

ABM Industries (ABM) has put fresh numbers on the table for Q2 2026, with revenue of US$2.3 billion, basic EPS of US$0.73 and net income, excluding extra items, of US$43.2 million. The company has seen revenue move from US$2.1 billion in Q2 2025 to US$2.3 billion in Q2 2026, while basic EPS has gone from US$0.67 to US$0.73 over the same period. This sets up this quarter as a clean check on how much of that top line is turning into profit. Margins are front and center in this release, giving...

Thermo Fisher Scientific (TMO) is back in focus after unveiling its Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the ASMS 2026 conference, refocusing attention on its high-end analytical instruments portfolio. See our latest analysis for Thermo Fisher Scientific. The stock has come under pressure in recent months, with the share price down 20.2% year to date and weaker over the past quarter. However, the 1 year total shareholder return of 18.07% remains positive,...

Recent share performance and business scale Ball (BALL) has drawn attention after a stretch of weaker share performance, with the stock down 10% over the past month and 15% over the past 3 months, prompting investors to reassess the business. The company focuses on aluminum packaging for beverage, personal care, and household products, generating revenue of US$13.7b and net income of US$936.0m across its global operations. See our latest analysis for Ball. At a share price of US$52.92, Ball’s...

In late May 2026, Red Cat Holdings’ Blue Ops unit moved its Variant 7 uncrewed surface vessel into full-rate U.S. production, while its drones were integrated into Safe Pro Group’s AI-enabled Threat Analysis Kit for the U.S. Army and shortlisted in the Pentagon’s Drone Dominance Program. Together with acquisitions in swarm robotics and wireless power, these developments broaden Red Cat’s presence across air and maritime defense robotics and deepen its role in AI-enabled battlefield systems...

In late May 2026, Precigen reported updated long-term follow-up data showing sustained complete responses and no new safety issues for PAPZIMEOS, which had already received full FDA approval and seven-year US market exclusivity as the first and only therapy for adults with recurrent respiratory papillomatosis. The durability of response, with most complete responders remaining surgery-free for at least three years and some beyond four years, underlines PAPZIMEOS’s role as a new immunotherapy...

Millrose Properties Stock Snapshot After Recent Trading Moves Millrose Properties (MRP) has drawn fresh attention after recent trading left the stock at US$28.93, with a move of about 0.4% on the day and a gain over the past week. Over the past month the stock is up about 2.6%, while performance over the past 3 months shows a decline of roughly 2.8%. Over the past year, total return is about 15.6%, giving investors a mixed but constructive set of recent price signals to weigh. See our latest...

Cabot (CBT) is back on investor radar after its recent share performance, with the stock closing at US$80.88 and showing mixed returns over the past week, month, and past 3 months. See our latest analysis for Cabot. That recent pullback, including a 1 day share price return of down 2.6% and 7 day share price return of down 7.6%, comes after a stronger run. The 90 day share price return of 15.5% and 1 year total shareholder return of 10.4% may indicate changing confidence in Cabot’s earnings...

SharkNinja (SN) has turned attention to design with its new Shark Home Luxe Collection, a cross-category color lineup for its latest PowerDetect vacuums, aiming to appeal to more style-focused households. See our latest analysis for SharkNinja. Despite the design-focused launches of the Luxe Collection and Ninja AutoBarista, SharkNinja’s share price has eased over the past week and day. However, its 1-year total shareholder return of 37.33% and 90-day share price return of 7.85% still point...

Chewy (NYSE:CHWY) has agreed to acquire Modern Animal, a network of physical veterinary clinics. The deal expands Chewy's reach in in-person pet health services and connects Modern Animal clinics with Chewy's e-commerce and pharmacy platforms. This move extends Chewy's prior efforts in AI and virtual vet care into a broader offline and online model. For you as an investor, this development sits at the intersection of pet health, e-commerce and brick-and-mortar services. Chewy already runs a...

If you are wondering whether Natural Resource Partners at around US$105.51 is still offering value or has already run too far, it helps to step back and look at what the numbers are really saying about the stock. The share price performance is mixed, with the stock up 1.5% over the last week and 1.4% year to date, while it has declined 8.4% over the past month but is up 11.3% over the past year and has risen by a very large amount over five years to roughly seven times the starting...

Wondering if Ares Management at around US$125.65 is a bargain or just expensive growth priced in already? This article breaks down what the current share price might be saying about value. The stock is up 1.4% over the past month, but has fallen 24.5% year to date and 25.3% over the past year, even though the 3 year and 5 year returns of 48.8% and 147.3% show that longer term holders have seen very different results. Recent attention on Ares Management has been driven less by a single...

PepsiCo, ticker NasdaqGS:PEP, has launched its Adrenaline Rush energy drink brand in India. The new product expands PepsiCo's energy drinks portfolio alongside its existing Sting brand. The move targets growing demand for functional beverages in one of PepsiCo's key emerging markets. For investors watching NasdaqGS:PEP, the launch of Adrenaline Rush in India comes as the stock trades around $141.92, with a return of 13.5% over the past year and 12.6% over the past 5 years. The company is...